Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:10 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study to Evaluate the Safety and Efficacy of AZD5718 in Participants With Proteinuric Chronic Kidney Disease
NCT04492722 · AstraZeneca · PHASE2 · terminated · last registry update 2024-12-20 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The Sponsor decided to terminate the study early due to lack of efficacy. There were no safety concerns related to the study.” | – | Registry record, AstraZeneca |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against SLC5A2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-12-19Phase 3 first posted: Instituto Mexicano del Seguro Social, Dapagliflozin 10 MG Oral Tablet + Semaglutide (Rybelsus®) (NCT07295223)
- 2025-12-18Also stopped (withdrawn): Eurofarma Laboratorios S.A., N0892 + Januvia® + Glifage XR® + Placebo (NCT06560333)
- 2025-12-12Phase 3 first posted: University of Cologne, Dapagliflozin 10 mg + Matching Placebo (NCT07280585)
- 2025-12-11Also stopped (terminated): Jinling Hospital, China, Finerenone (BAY 94-8862) + Empagliflozin 10 mg (NCT06818305)
- 2025-10-31Results posted on the registry: Merck Sharp & Dohme LLC, Ertugliflozin 5 mg + Ertugliflozin 15 mg (NCT04029480)
- 2025-10-21Results posted on the registry: Wake Forest University Health Sciences, Insulin (Humulin® R U-100) + Empagliflozin 10 MG (NCT05081219)
- 2025-10-15Results posted on the registry: Centro Medico Nacional Siglo XXI IMSS, Dapagliflozin/Metformin + Metformin (NCT03968224)
- 2025-10-09Phase 3 first posted: Mansoura University, Dapagliflozin + Empagliflozin (NCT07214818)
- 2025-10-08Results posted on the registry: University of California, San Francisco, Dapagliflozin (NCT04818034)
- 2025-08-06Phase 3 first posted: Boehringer Ingelheim, Empagliflozin + Placebo (NCT07107945)
- 2025-07-14Phase 3 first posted: Boehringer Ingelheim, Vicadrostat + Empagliflozin (NCT07064473)
- 2025-07-09Phase 3 first posted: The University of Texas Health Science Center at San Antonio, Dapagliflozin 10mg Tab + Pioglitazone 15 MG and 30mg (NCT07056699)
- 2025-06-26Phase 3 first posted: Christian Schulze, Empagliflozin 10 MG Oral Tablet [Jardiance] + Placebo (NCT07038356)
- 2025-06-24Phase 3 first posted: Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair, Farxiga® (dapagliflozin) + Onglyza® (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes + China Import (dapagliflozin) + China Import (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes (NCT07033585)
- 2025-06-18Phase 3 first posted: CSPC Ouyi Pharmaceutical Co., Ltd., Prusogliptin, Dapagliflozin(high dose), Dapagliflozin (low dose) placebo, plus metformin XR + Prusogliptin placebo, Dapagliflozin(high dose), Dapagliflozin (low dose) placebo, plus metformin XR (NCT07026968)
- 2025-06-17Phase 3 first posted: Assistance Publique - Hôpitaux de Paris, Dapagliflozin 10 MG Oral Tablet [Farxiga] + One tablet of placebo of dapagliflozin 10 mg (NCT07025629)
- 2025-05-02Phase 3 first posted: Subodh Verma, Empagliflozin 10 mg (NCT06955260)
- 2025-04-20Phase 3 first posted: Boehringer Ingelheim, vicadrostat + empagliflozin (NCT06935370)
- 2025-04-02Phase 3 first posted: Ottawa Heart Institute Research Corporation, Dapagliflozin (DAPA) + Placebo (NCT06907251)
- 2025-03-21Phase 3 first posted: Children's Hospital of Fudan University, Dapagliflozin+Standard Treatment for 12 weeks,washout period for 4 weeks，then Standard Treatment alone for12 weeks + Standard Treatment alone for 12 weeks ,washout period for 4 weeks ,then Dapagliflozin+Standard Treatment for 12 weeks (NCT06890143)
- 2025-01-20Phase 3 first posted: Mansoura University, Dapagliflozin 10mg + Acetazolamide 500mg (NCT06783166)
- 2025-01-13Phase 3 first posted: CMG Pharmaceutical Co. Ltd, CMG190303(Dapagliflozin/Rosuvastatin) + Comparator 1: Dapagliflozin/Rosuvastatin placebo (NCT06772168)
- 2025-01-06Phase 3 first posted: Al-Azhar University, Dapagliflozin (DAPA) (NCT06759077)
- 2024-12-27Phase 3 first posted: Tanta University, Dapagliflozin placebo + Placebo (NCT06750458)
- 2024-12-19Phase 3 first posted: AstraZeneca, Baxdrostat/dapagliflozin + Placebo/dapagliflozin (NCT06742723)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision